Business Context and Reporting Period
This Form 8-K was filed by Bond Laboratories, Inc. (referred to in metadata as FITLIFE BRANDS, INC.) on June 26, 2008. The report details a significant unregistered sale of equity securities and related financing transactions.
Key Financial Metrics and Transaction Details
- Total Financing Amount: $4,000,000 aggregate purchase price.
- Initial Closing (June 26, 2008): $3,000,000 funded.
- Second Closing (by July 26, 2008): $1,000,000 to be funded upon mutual agreement.
- Security Issuance:
- Common Shares issued at $1.00 per share.
- Warrants issued to purchase 60% of the number of shares purchased, with a 7-year term and an initial exercise price of $1.25.
- Series A Convertible Preferred Stock issued to prevent investors from exceeding a 9.99% ownership threshold.
- Debt Conversion: $210,000 in principal of promissory bridge notes (plus accrued interest) were converted into shares at a 120% premium to principal.
- Related Party Transaction: CEO Scott Landow sold 5,000,000 shares of Series A Convertible Preferred Stock to purchasers for $100,000.
- Placement Agent Fees: Chardan Capital Markets, LLC and Burnham Hill Partners each received 5% of gross proceeds, 5% of warrants, and 4% of the Series A Preferred Stock sold by the CEO.
Material Changes and Performance Conditions
The filing outlines specific performance milestones tied to the financing. If the Company fails to meet the following targets by December 31, 2008, it must issue additional shares to purchasers:
- Revenue Target: Aggregate GAAP revenue of at least $3,800,000 for the calendar year.
- Profitability Target: Positive adjusted EBITDA for the fourth quarter (excluding specific marketing/endorsement fees but including related travel/entertainment expenses).
- Penalty Mechanism: Failure to meet targets triggers an issuance of additional shares calculated based on a price floor of $0.70 per share.
Outlook, Governance, and Risks
- Board Composition: The Company agreed to amend its Bylaws by September 30, 2008, to increase the Board of Directors to five seats. Purchasers representing a majority of outstanding shares will nominate two directors.
- Registration Rights: The Company agreed to file a Form S-1 for the public resale of the common stock and warrant shares.
- Right of First Offer: The Company retains a right of first offer on any private sale or transfer of 25% or more of the shares/warrants acquired by purchasers.
- Participation Rights: Purchasers have pro rata participation rights in future equity or debt offerings for two years.
- Risk Factors: The filing does not provide specific quantitative risk factors beyond the performance-based share issuance penalty and the dilution inherent in the warrant and preferred stock structure.
Investor Verification Checklist
- Verify the completion of the Second Closing ($1,000,000) by July 26, 2008.
- Confirm the Company's audited financial statements for the year ending December 31, 2008, to determine if the $3.8M revenue and positive Q4 EBITDA targets were met.
- Review the amended Bylaws to confirm the Board of Directors was expanded to five seats and the appointment of the two investor-nominated directors.
- Check for the filing of the Form S-1 registration statement for the resale of the issued securities.
- Monitor the dilution impact from the conversion of bridge notes and the potential issuance of penalty shares if performance targets are missed.